
Every day, doctors are faced with the dilemma of starting a postexposure prophylaxis (PEP) against HIV, HBV and HCV. A 28 days course of highly active antiretroviral therapy, chosen on the basis of the source's HIV resistance profile, should be initiated, as soon as possible, to reduce the likelihood of HIV transmission. Complete vaccination against HBV (3 doses) is associated with a 100% seroprotection in children and 95% in adults. There is no specific prophylaxis against HCV. Because of the complexity of these situations, we have edited local guidelines, which take into account not only international and Swiss recommendations, but also our experts' opinions. It is important to stress that PEP does not replace standard precautions.
Anti-Retroviral Agents, Humans, HIV Infections, Hepatitis B Vaccines, Hepatitis B, Antiviral Agents, Hepatitis C
Anti-Retroviral Agents, Humans, HIV Infections, Hepatitis B Vaccines, Hepatitis B, Antiviral Agents, Hepatitis C
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
